Rationale for pertussis booster vaccination throughout life in Europe - PubMed

Review

Rationale for pertussis booster vaccination throughout life in Europe

Fred Zepp et al. Lancet Infect Dis. 2011 Jul.

Abstract

Although the introduction of universal pertussis immunisation in infants has greatly reduced the number of reported cases in infants and young children, disease incidence has been increasing in adolescents and adults in recent years. This changing epidemiological pattern is probably largely attributable to waning immunity after natural infection or vaccination. Furthermore, improved diagnostic testing, active surveillance, changes in disease susceptibility, vaccine characteristics, and increased awareness of the disease might also be contributing factors. Susceptibility to pertussis in adolescents and adults results not only in direct morbidity in these age groups, but also poses a transmission risk to susceptible non-immune infants who are often too young to be vaccinated. Because vaccination schedules vary across Europe, we review the pertussis situation in this region and propose considerations for use of pertussis booster vaccinations at different ages to reduce individual morbidity and transmission from present rates and increase herd protection.

Similar articles

• Pertussis immunisation in adolescents and adults--Bordetella pertussis epidemiology should guide vaccination recommendations.

  Heininger U, Cherry JD. Heininger U, et al. Expert Opin Biol Ther. 2006 Jul;6(7):685-97. doi: 10.1517/14712598.6.7.685. Expert Opin Biol Ther. 2006. PMID: 16805708 Review.

• Epidemiological and immunological reasons for pertussis vaccination in adolescents and adults.

  Nitsch-Osuch A, Korzeniewski K, Kuchar E, Zielonka T, Życińska K, Wardyn K. Nitsch-Osuch A, et al. Respir Physiol Neurobiol. 2013 Jun 1;187(1):99-103. doi: 10.1016/j.resp.2013.02.007. Epub 2013 Feb 16. Respir Physiol Neurobiol. 2013. PMID: 23419520 Review.

• Using computer simulations to compare pertussis vaccination strategies in Australia.

  Hethcote HW, Horby P, McIntyre P. Hethcote HW, et al. Vaccine. 2004 Jun 2;22(17-18):2181-91. doi: 10.1016/j.vaccine.2003.11.053. Vaccine. 2004. PMID: 15149775

• Re-emergence of pertussis: what are the solutions?

  Libster R, Edwards KM. Libster R, et al. Expert Rev Vaccines. 2012 Nov;11(11):1331-46. doi: 10.1586/erv.12.118. Expert Rev Vaccines. 2012. PMID: 23249233 Review.

• Immunization against pertussis in adolescents and adults.

  Esposito S, Principi N; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Vaccine Study Group (EVASG). Esposito S, et al. Clin Microbiol Infect. 2016 Dec 1;22 Suppl 5:S89-S95. doi: 10.1016/j.cmi.2016.01.003. Epub 2016 Apr 26. Clin Microbiol Infect. 2016. PMID: 27130670

Cited by

• Vaccination recommendations for Germany.

  Wiese-Posselt M, Tertilt C, Zepp F. Wiese-Posselt M, et al. Dtsch Arztebl Int. 2011 Nov;108(45):771-9; quiz 780. doi: 10.3238/arztebl.2011.0771. Epub 2011 Nov 4. Dtsch Arztebl Int. 2011. PMID: 22163258 Free PMC article. Review.

• Transversal sero-epidemiological study of Bordetella pertussis in Tehran, Iran.

  Noel G, Badmasti F, Nikbin VS, Zahraei SM, Madec Y, Tavel D, Aït-Ahmed M, Guiso N, Shahcheraghi F, Taieb F. Noel G, et al. PLoS One. 2020 Sep 1;15(9):e0238398. doi: 10.1371/journal.pone.0238398. eCollection 2020. PLoS One. 2020. PMID: 32870922 Free PMC article.

• Toward a new vaccine for pertussis.

  Robbins JB, Schneerson R, Kubler-Kielb J, Keith JM, Trollfors B, Vinogradov E, Shiloach J. Robbins JB, et al. Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3213-6. doi: 10.1073/pnas.1324149111. Epub 2014 Feb 20. Proc Natl Acad Sci U S A. 2014. PMID: 24556987 Free PMC article.

• Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States.

  Pawloski LC, Queenan AM, Cassiday PK, Lynch AS, Harrison MJ, Shang W, Williams MM, Bowden KE, Burgos-Rivera B, Qin X, Messonnier N, Tondella ML. Pawloski LC, et al. Clin Vaccine Immunol. 2014 Feb;21(2):119-25. doi: 10.1128/CVI.00717-13. Epub 2013 Nov 20. Clin Vaccine Immunol. 2014. PMID: 24256623 Free PMC article.

• c-di-GMP enhances protective innate immunity in a murine model of pertussis.

  Elahi S, Van Kessel J, Kiros TG, Strom S, Hayakawa Y, Hyodo M, Babiuk LA, Gerdts V. Elahi S, et al. PLoS One. 2014 Oct 15;9(10):e109778. doi: 10.1371/journal.pone.0109778. eCollection 2014. PLoS One. 2014. PMID: 25333720 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information